Kim D W, Joshi G P, White P F, Johnson E R
Department of Anesthesiology and Pain Management, University of Texas Southwestern Medical Center, Dallas 75235-9068, USA.
Anesth Analg. 1996 Oct;83(4):818-22. doi: 10.1097/00000539-199610000-00029.
This study was designed to examine the interactions between mivacurium and rocuronium or vecuronium when administered during a standardized anesthetic technique. Seventy healthy women undergoing abdominal hysterectomy procedures with a standardized thiopental-sufentanil-desflurane-nitrous oxide anesthetic technique were randomly assigned to one of seven treatment groups (10 patients each). After a tracheal intubating dose of vecuronium 100 micrograms/kg (Groups 1 and 2), rocuronium 600 micrograms/kg (Groups 3 and 4), or mivacurium 250 micrograms/kg (Groups 5, 6, and 7), patients received vecuronium, 25 micrograms/kg (Groups 1 and 6), rocuronium 150 micrograms/kg (Groups 3 and 7), or mivacurium 50 micrograms/kg (Groups 2, 4, and 5) for maintenance of neuromuscular blockade. Neuromuscular function was assessed using electromyography, with a train-of-four mode of stimulation at the wrist every 10 s. The clinical duration (time for T1 to return to 25% of baseline) of the maintenance dose of mivacurium was significantly longer after an intubating dose of rocuronium (40 +/- 8 min) and vecuronium (28 +/- 6 min) than after mivacurium (12 +/- 3 min). The clinical duration of maintenance doses of vecuronium (18 +/- 6 min) and rocuronium (13 +/- 2 min) were significantly shorter after an intubating dose of mivacurium than that after an intubating dose of vecuronium (30 +/- 5 min) or rocuronium (42 +/- 12 min), respectively. These data suggest that with consecutive administration of neuromuscular blocking drugs, the initial duration of action depends more on the kinetics of the first neuromuscular blocking drug than the subsequent drug. Thus, there appears to be no clinical advantage in using mivacurium for maintenance of neuromuscular blockade after initial administration of rocuronium or vecuronium.
本研究旨在探讨在标准化麻醉技术下给予米库氯铵与罗库溴铵或维库溴铵时它们之间的相互作用。70名接受腹部子宫切除术的健康女性采用标准化硫喷妥钠-舒芬太尼-地氟醚-氧化亚氮麻醉技术,被随机分配到7个治疗组之一(每组10例患者)。在给予气管插管剂量的维库溴铵100微克/千克(第1组和第2组)、罗库溴铵600微克/千克(第3组和第4组)或米库氯铵250微克/千克(第5、6和7组)后,患者接受维库溴铵25微克/千克(第1组和第6组)、罗库溴铵150微克/千克(第3组和第7组)或米库氯铵50微克/千克(第2、4和5组)以维持神经肌肉阻滞。使用肌电图评估神经肌肉功能,每隔10秒在腕部采用四个成串刺激模式。在给予插管剂量的罗库溴铵(40±8分钟)和维库溴铵(28±6分钟)后,米库氯铵维持剂量的临床持续时间(T1恢复至基线的25%的时间)显著长于给予米库氯铵后(12±3分钟)。在给予插管剂量的米库氯铵后,维库溴铵(18±6分钟)和罗库溴铵(13±2分钟)维持剂量的临床持续时间分别显著短于给予插管剂量的维库溴铵(30±5分钟)或罗库溴铵(42±12分钟)后。这些数据表明,连续给予神经肌肉阻滞药物时,初始作用持续时间更多地取决于第一种神经肌肉阻滞药物的动力学而非随后的药物。因此,在初始给予罗库溴铵或维库溴铵后使用米库氯铵维持神经肌肉阻滞似乎没有临床优势。